Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-1606 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment
Cmax of ABBV-1606
Tmax of ABBV-1606
AUCt of ABBV-1606
AUCinf of ABBV-1606
β of ABBV-1606
t1/2 of ABBV-1606
CL/F of ABBV-1606
Vz/F of ABBV-1606
Dose Normalized Cmax of ABBV-1606 will be assessed.
Dose Normalized AUC of ABBV-1606 will be assessed.
| Arm | Type | Description |
|---|---|---|
| ABBV-1606 or Placebo Group 1 | EXPERIMENTAL | Participants will receive a single oral dose of ABBV-1606 or placebo group 1 on day 1. |
| ABBV-1606 or Placebo Group 2 | EXPERIMENTAL | Participants will receive a single oral dose of ABBV-1606 or placebo group 2 on day 1. |
| ABBV-1606 or Placebo Group 3 | EXPERIMENTAL | Participants will receive a single oral dose of ABBV-1606 or placebo group 3 on day 1. |
| ABBV-1606 or Placebo Group 4 | EXPERIMENTAL | Participants will receive a single oral dose of ABBV-1606 or placebo group 4 on day 1. |
| ABBV-1606 or Placebo Group 5 | EXPERIMENTAL | Participants will receive a single oral dose of ABBV-1606 or placebo group 5 on day 1. |
| Name | Type | Description |
|---|---|---|
| ABBV-1606 | DRUG | Oral Solution |
| Placebo | DRUG | Oral Solution |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * Total body weight \> 50.0 kg at Screening. * A condition of general good health, based upon the results of a...